EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, GNPX: Genprex Inc

13 Nov 25 15:59
LAST:

4.115

CHANGE:
 0.46		OPEN:
4.820		HIGH:
4.820		ASK:
0.000		VOLUME:
239.0K
CHG(%):
10.00		PREV:
4.600		LOW:
4.050		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Nov 254.6004.6894.0504.140289.3K
12 Nov 254.1505.0004.0204.600770.7K
11 Nov 253.9204.0703.9004.050206.5K
10 Nov 254.3704.5803.9004.000243.3K
07 Nov 254.7104.7554.1604.210230.5K
06 Nov 255.9606.3004.6004.690416.3K
05 Nov 254.6106.2504.6005.850497.0K
04 Nov 255.0205.1804.6204.700194.6K
03 Nov 255.3705.7805.1805.300192.5K
31 Oct 256.0806.2225.7305.770215.8K

COMPANY PROFILE

Name:Genprex Inc
About:Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Sector:Healthcare
Industry:Biotechnology
Address:3300 Bee Cave Road, Austin, TX, United States, 78746
Website:https://www.genprex.com
CUSIP:372446104
CIK:0001595248
ISIN:US3724461047
FIGI:BBG00F7T0157
LEI:549300KS9771JZ234890

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.29 
Forward P/E:-0.11 
Price to Book:5.82 
EPS Ratio:0.85 
Shares:42.91M 
Market Cap:176.56M 

TECHNICAL INDICATORS

MA5:4.202.1%
MA10:4.7315.0%
MA20:5.8943.2%
MA50:2.5164.2%
MA100:1.37200.8%
MA200:0.85385.8%
STO9:6.09 
STO14:2.38 
RSI14:19.51 
WPR14:-97.05 
MTM14:-4.61
ROC14:-0.53 
ATR:0.98 
Week High:6.3053.1%
Week Low:3.905.5%
Month High:12.97215.2%
Month Low:0.17385.8%
Year High:12.97215.2%
Year Low:0.142,839.3%
Volatility:488.04 

RECENT SPLITS

Date Ratio
02 Feb 20241-40